A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival

Genes and Development

Volumn 27, Issue 13, 2013, Pages 1462-1472

  Zheng, Siyuan ^a   Fu, Jun ^a   Vegesna, Rahulsimham ^a   Mao, Yong ^a   Heathcock, Lindsey E ^a   Torres Garcia, Wandaliz ^a   Ezhilarasan, Ravesanker ^a   Wang, Shuzhen ^a   McKenna, Aaron ^b   Chin, Lynda ^a   Brennan, Cameron W ^c   Alfred Yung, W K ^a   Weinstein, John N ^a   Aldape, Kenneth D ^a   Sulman, Erik P ^a   Chen, Ken ^a   Koul, Dimpy ^a   Verhaak, Roel G W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene fusion; Genomic instability; Genomic rearrangement; Glioblastoma multiforme; Intragenic breakpoint; The Cancer Genome Atlas

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYTOSINE; GUANINE; PROTEIN MDM2;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CHROMOSOME MUTATION; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; GENE FUSION; GENE INSERTION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA CELL; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL;

GENE FUSION; GENOMIC INSTABILITY; GENOMIC REARRANGEMENT; GLIOBLASTOMA MULTIFORME; INTRAGENIC BREAKPOINT; THE CANCER GENOME ATLAS;

ANIMALS; CARRIER PROTEINS; CHROMOSOME BREAKAGE; CYCLIN-DEPENDENT KINASE 4; DNA COPY NUMBER VARIATIONS; GENE FUSION; GENE REARRANGEMENT; GENOMIC INSTABILITY; GLIOBLASTOMA; MICE; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS;

MURINAE;

EID: 84879764400     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.213686.113     Document Type: Article

References (53)

1. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, Kane AB, Testa JR. 2009. Activated TNF-a/NFkB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci 106: 3420-3425.
2. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, Macdonald TY, Ghandi M, et al. 2013. Punctuated evolution of prostate cancer genomes. Cell 153: 666-677.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
4. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, et al. 2011. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet 43: 964-968.
5. Bengtsson H, Wirapati P, Speed TP. 2009. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25: 2149-2156.
6. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
7. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci 104: 20007-20012.
8. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
9. The Cancer Genome Atlas Research Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
10. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
11. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, et al. 2012. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30: 413-421.
12. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, McGrath SD, Wendl MC, Zhang Q, Locke DP, et al. 2009. BreakDancer: An algorithm for high-resolution mapping of genomic structural variation. Nat Methods 6: 677-681.
13. Chin L, Hahn WC, Getz G, Meyerson M. 2011. Making sense of cancer genomic data. Genes Dev 25: 534-555.
14. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, et al. 2011. Glioblastoma-derived epidermal growth factor receptor carboxyl- terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 71: 7587-7596.
15. Chu K, Niu X, Williams LT. 1995. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci 92: 11894-11898.
16. Ciriello G, Cerami EG, Sander C, Schultz N. 2011. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22: 398-406.
17. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson SF. 2010. U87MG decoded: The genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 6: e1000832.
18. Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES, Meyerson M, Beroukhim R, Getz G. 2012. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangementinduced hypermutability. Genome Res 23: 228-235.
19. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 756-784.
20. Errani C, Sung YS, Zhang L, Healey JH, Antonescu CR. 2012. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 205: 12-17.
21. Fenstermaker RA, Ciesielski MJ. 2000. Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma. Oncogene 19: 4542-4548.
22. Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Alfred Yung WK. 2013. Novel HSP90 inhibitor NVPHSP990 targets cell-cycle regulators to ablate olig2-positive glioma tumor-initiating cells. Cancer Res 73: 3062-3074.
23. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. 2007. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710.
24. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
25. Henrich KO, Bauer T, Schulte J, Ehemann V, Deubzer H, Gogolin S, Muth D, Fischer M, Benner A, Konig R, et al. 2011. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 71: 3142-3151.
26. Korbel JO, Campbell PJ. 2013. Criteria for inference of chromothripsis in cancer genomes. Cell 152: 1226-1236.
27. Kuttler F, Mai S. 2007. Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. Semin Cancer Biol 17: 56-64.
28. Lalic H, Volavsek C, Radosevic-Stasic B. 2004. Chromosomal instability and double minute chromosomes in a breast cancer patient. Acta Med Okayama 58: 51-58.
29. Lapenna S, Giordano A. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
30. Lawson AR, Hindley GF, Forshew T, Tatevossian RG, Jamie GA, Kelly GP, Neale GA, Ma J, Jones TA, Ellison DW, et al. 2011. RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Res 21: 505-514.
31. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. 2012. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
32. Liu W, He L, Ramirez J, Ratain MJ. 2009. Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. Clin Cancer Res 15: 7602-7607.
33. Lukusa T, Fryns JP. 2008. Human chromosome fragility. Biochim Biophys Acta 1779: 3-16.
34. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
35. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
36. Patel AG, Sarkaria JN, Kaufmann SH. 2011. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci 108: 3406-3411.
37. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, Jager N, Remke M, Shih D, Northcott PA, et al. 2012. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148: 59-71.
38. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, Straatman H, Larizza L, Schoenmakers EF. 2006. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 25: 1571-1583.
39. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, et al. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337: 1231-1235.
40. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20: 810-817.
41. Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N, Mabanta L, Bigner D, Yan H, Jean W, et al. 2008. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 68: 2564-2569.
42. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S. 2013. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110: 4009-4014.
43. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
44. Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D'Addabbo P, Daniele G, L'Abbate A, Macchia G, Surace C, Kok K, et al. 2010. Gene amplification as double minutes or homogeneously staining regions in solid tumors: Origin and structure. Genome Res 20: 1198-1206.
45. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
46. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, et al. 2012. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22: 425-437.
47. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, et al. 2012. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci 109: 3041-3046.
48. Thomas L, Stamberg J, Gojo I, Ning Y, Rapoport AP. 2004. Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: Two case reports and a review of literature. Am J Hematol 77: 55-61.
49. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, et al. 2009. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci 106: 9435-9440.
50. Venkatraman ES, Olshen AB. 2007. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23: 657-663.
51. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
52. Vogt N, Lefevre SH, Apiou F, Dutrillaux AM, Cor A, Leuraud P, Poupon MF, Dutrillaux B, Debatisse M, Malfoy B. 2004. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci 101: 11368-11373.
53. Zheng S, Chheda MG, Verhaak RG. 2012. Studying a complex tumor: Potential and pitfalls. Cancer J 18: 107-114.